Implantica Yönetim

Yönetim kriter kontrolleri 3/4

Implantica CEO'su Peter Forsell, Jan2015 tarihinde atandı, in görev süresi 9.83 yıldır. in toplam yıllık tazminatı € 204.27K olup, şirket hissesi ve opsiyonları dahil olmak üzere 99.8% maaş ve 0.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 87.11% ine doğrudan sahiptir ve bu hisseler € 772.50M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.8 yıldır.

Anahtar bilgiler

Peter Forsell

İcra Kurulu Başkanı

€204.3k

Toplam tazminat

CEO maaş yüzdesi	99.8%
CEO görev süresi	9.8yrs
CEO sahipliği	87.1%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Peter Forsell'un ücretlendirmesi Implantica'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-€25m
Jun 30 2024	n/a	n/a	-€24m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€204k	€204k	-€24m
Sep 30 2023	n/a	n/a	-€20m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€21m
Dec 31 2022	€200k	€200k	-€21m

Tazminat ve Piyasa: Peter 'nin toplam tazminatı ($USD 216.16K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.42M ).

Tazminat ve Kazançlar: Peter şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Peter Forsell (70 yo)

9.8yrs

Görev süresi

€204,274

Tazminat

Dr. Peter Forsell founded Implantica AG in 2015 and serves as its Chief Executive Officer since 2015.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Forsell	Founder & CEO	9.8yrs	€204.27k	87.11% € 772.5m
Andreas Öhrnberg	Chief Financial Officer	4.8yrs	Veri yok	0.0084% € 74.8k
Stephan Siegenthaler	Chief Strategy Officer & Board Member	no data	Veri yok	0.32% € 2.8m
Nicole Pehrsson	Chief Corporate Affairs Officer	2.4yrs	Veri yok	0.17% € 1.5m
Amit Kukreja	Chief Market Access & Strategy Officer	3.8yrs	Veri yok	Veri yok
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: 8IM1 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stephan Siegenthaler	Chief Strategy Officer & Board Member	4.8yrs	Veri yok	0.32% € 2.8m
Jörg von Manger-Koenig	Company Secretary & Member of Advisory Board	no data	Veri yok	Veri yok
Liselott Kilaas	Independent Chair of the Board	4.8yrs	€36.02k	0.0099% € 88.1k
Tomas Puusepp	Independent Board Member	4.3yrs	€50.43k	0.0071% € 62.6k
Felix Zulauf	Member of Advisory Board	no data	Veri yok	Veri yok
Johan Bojs	Vice-Chairman of the Board	4.8yrs	€10.29k	0.047% € 414.6k
Piet Pattyn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Steven Wilson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kaspar Z'graggen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8IM1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).

Implantica Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Chief Corporate Affairs Officer recently bought €108k worth of stock

Insufficient new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Recent updates

Third quarter 2024 earnings released: €0.09 loss per share (vs €0.019 loss in 3Q 2023)

Implantica AG to Report Q4, 2024 Results on Feb 14, 2025

Implantica AG (publ.) Submits FDA PMA Application Clinical Module 2 for RefluxStop for U.S. Market Approval

Implantica AG to Report Q3, 2024 Results on Nov 15, 2024

Implantica Ag (Publ.) Announces Highly Successful 2024 American Foregut Society Meeting Where Refluxstop Received Remarkable Pre- Launch Market Feedback

Implantica AG announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop

Implantica AG Announces Excellent Data from an Independent Study of 158 RefluxStop Patients from Two Centers in Germany - Presented at the AUGIS Meeting in UK

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Second quarter 2024 earnings released: €0.09 loss per share (vs €0.018 loss in 2Q 2023)

Implantica AG Announces Refluxstop Pivotal 4-Year Study Results Published in the Prestigious Journal Surgical Endoscopy

Implantica Announces Continuing Progress in Modular PMA Application to FDA for Refluxstop

Implantica Announces New Health-economics Data Publication Showing RefluxStop's Superior Cost-Effectiveness for the Swiss Healthcare System

First quarter 2024 earnings released: €0.05 loss per share (vs €0.016 loss in 1Q 2023)

Implantica Submits U.S. FDA Premarket Approval (PMA) Application for RefluxStop® (first module)

Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process

Full year 2023 earnings released: €0.34 loss per share (vs €0.074 loss in FY 2022)

Implantica AG to Report Fiscal Year 2023 Results on Apr 26, 2024

Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin

Chief Corporate Affairs Officer recently bought €108k worth of stock

Third quarter 2023 earnings released: €0.019 loss per share (vs €0.02 loss in 3Q 2022)

Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK

Insufficient new directors

Implantica AG to Report Q4, 2023 Results on Feb 20, 2024

Implantica AG to Report Q2, 2023 Results on Aug 24, 2023

Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago

Implantica AG to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: €0.074 loss per share (vs €0.055 loss in FY 2021)

Full year 2022 earnings released: €0.30 loss per share (vs €0.055 loss in FY 2021)

Third quarter 2022 earnings released: €0.08 loss per share (vs €0.015 loss in 3Q 2021)

Third quarter 2022 earnings released: €0.08 loss per share (vs €0.015 loss in 3Q 2021)

High number of new and inexperienced directors

Second quarter 2022 earnings released: €0.08 loss per share (vs €0.042 loss in 2Q 2021)

First quarter 2022 earnings released: €0.07 loss per share (vs €0.03 loss in 1Q 2021)

Implantica AG to Report Q4, 2022 Results on Feb 17, 2023

Implantica AG to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Full year 2021 earnings released: €0.055 loss per share (vs €0.039 loss in FY 2020)

Implantica Ag Announces Launch of Refluxstop™ in Uk

Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Implantica AG to Report Q4, 2021 Results on Feb 18, 2022

Implantica AG Appoints Paul Meadas as Chief Operating Officer

High number of new and inexperienced directors

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vice-Chairman of the Board recently sold €1.4m worth of stock

Second quarter 2021 earnings released: €0.04 loss per share (vs €0.10 loss in 2Q 2020)

Implantica Achieves Regulatory Authorisation for RefluxStop™ in New Zealand

Implantica AG (publ) Makes Headway in Italy and Spain with Its Medical Device RefluxStop™

Implantica Advances in Sweden with its Medical Device Refluxstop™

Revenue misses expectations

Implantica AG to Report Q4, 2020 Results on Feb 25, 2021

Implantica AG (publ)'s RefluxStop™ Makes Strides in the UK

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş